Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Invesco NASDAQ 100 ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 9× Halozyme Therapeutics Inc. Common Stock's market cap, and Invesco NASDAQ 100 ETF is more actively traded (2,866,236 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| HALO | QQQM | |
|---|---|---|
Market Cap | $12.58B | $113.40B |
Volume | 2,179,278 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $115.22 | $312.76 |
52-Week Low | $61.63 | $229.87 |
Typical Hold Time | 1 Days | 54 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQM trades at $307.85, down 1.33% on the day, with a bullish technical outlook supported by moving averages. The ETF benefits from Nasdaq-100 exposure and a competitive 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show support at $305 and resistance at $311.
The outlook remains positive given Nasdaq-100 strength and lower fees than QQQ. Risks include market concentration in technology stocks and potential tax implications of distributions. Analyst sentiment favors QQQM for core growth allocations, though some prefer equal-weight alternatives for diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
